Bicycle Therapeutics plc American Depositary Shares BCYC
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 3 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $14.50 (+245.2% upside)
Key Stats
- Today's Range
- $4.19 – $4.44
- 50-Day Range
- $3.75 – $4.51
- 52-Week Range
- $3.75 – $9.16
- Volume
- 155K shs
- Average Volume
- 294K shs
- Market Cap
- $303.07 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.59
- Price / Sales
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Bicycle Therapeutics plc American Depositary Shares
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Related Stocks
Compare head-to-head: BCYC vs LLY·BCYC vs JNJ·BCYC vs ABBV·BCYC vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.